Effects of statins beyond lipid lowering: Potential for clinical benefits

被引:109
作者
Almuti, K
Rimawi, R
Spevack, D
Ostfeld, RJ
机构
[1] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA
[2] Montefiore Med Ctr, Div Cardiol, Bronx, NY 10467 USA
[3] Lutheran Med Univ, Dept Med, Brooklyn, NY USA
关键词
statin; lipid lowering; HMG-CoA;
D O I
10.1016/j.ijcard.2005.05.056
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The role of statin drugs in the reduction of serum lipids has been well documented. More recently, evidence suggesting that statins may positively impact many organ systems and disease states independent of lipid reduction has emerged. The term "pleiotropic effects" has been used to refer to these properties. We reviewed the evidence exploring Such potential effects. Methods: A search of the MEDLINE database was conducted for articles published between 1985 to 2005 on the pleiotropic and the lipid-lowering independent effects of statin drugs. The search terms "statin", "HMG-CoA reductase inhibitor", "pleiotropic effects", and "inflammation" were used. English language articles were selected for inclusion along with selected cross-references. Results: Numerous animal and clinical studies support the presence of a spectrum of beneficial effects for statins that are independent of their lipid-lowering properties. These effects are mediated by a variety of mechanisms and they suggest that the therapeutic role of statins may expand. Conclusion: Statins have shown great promise beyond their lipid-lowering effects. Ongoing and future Studies will help to further clarify the potential clinical impact of these "pleiotropic effects". (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:7 / 15
页数:9
相关论文
共 107 条
  • [61] Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease
    Nissen, SE
    Tuzcu, EM
    Schoenhagen, P
    Crowe, T
    Sasiela, WJ
    Tsai, J
    Orazem, J
    Magorien, RD
    O'Shaughnessy, C
    Ganz, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (01) : 29 - 38
  • [62] Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy
    Node, K
    Fujita, M
    Kitakaze, M
    Hori, M
    Liao, JK
    [J]. CIRCULATION, 2003, 108 (07) : 839 - 843
  • [63] INHIBITION OF THROMBOXANE BIOSYNTHESIS AND PLATELET-FUNCTION BY SIMVASTATIN IN TYPE IIA HYPERCHOLESTEROLEMIA
    NOTARBARTOLO, A
    DAVI, G
    AVERNA, M
    BARBAGALLO, CM
    GANCI, A
    GIAMMARRESI, C
    LAPLACA, FP
    PATRONO, C
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (02) : 247 - 251
  • [64] Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
    ODriscoll, G
    Green, D
    Taylor, RR
    [J]. CIRCULATION, 1997, 95 (05) : 1126 - 1131
  • [65] HYPERCHOLESTEROLEMIA INCREASES ENDOTHELIAL SUPEROXIDE ANION PRODUCTION
    OHARA, Y
    PETERSON, TE
    HARRISON, DG
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (06) : 2546 - 2551
  • [66] DIETARY CORRECTION OF HYPERCHOLESTEROLEMIA IN THE RABBIT NORMALIZES ENDOTHELIAL SUPEROXIDE ANION PRODUCTION
    OHARA, Y
    PETERSON, TE
    SAYEGH, HS
    SUBRAMANIAN, RR
    WILCOX, JN
    HARRISON, DG
    [J]. CIRCULATION, 1995, 92 (04) : 898 - 903
  • [67] Packard CJ, 1998, CIRCULATION, V97, P1440
  • [68] Immunomodulatory effects of statins: Mechanisms and potential impact on arteriosclerosis
    Palinski, W
    Tsimikas, S
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (06): : 1673 - 1681
  • [69] Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study
    Pedersen, TR
    Berg, K
    Cook, TJ
    Faergeman, O
    Haghfelt, T
    Kjekshus, J
    Miettinen, T
    Musliner, TA
    Olsson, AG
    Pyorala, K
    Thorgeirsson, G
    Tobert, JA
    Wedel, H
    Wilhelmsen, L
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (18) : 2085 - 2092
  • [70] PEDERSEN TR, 1994, LANCET, V344, P1383